Who is moving to which position
Resolved 9 September 2026Incoming appointee
1 itemTo respond to changes in the business environment surrounding the Company, further accelerate efforts to grow existing businesses and create new businesses, strengthen the management structure and speed up decision-making, the Company will transition to a co-representative structure with 2 representative directors and further reinforce its management foundation. Having the founder join the core of management as a representative director will further strengthen the Company's commitment to the research and development of regenerative medicine and accelerate these efforts.
| Item | Details |
|---|---|
| Resolution date | 9 September 2026 |
| Scheduled Appointment Date | Effective 9 September 2026 |
| Name of appointee | Tamai Katsuhito (玉井 克人) |
| Appointee's new position | Representative Director, Chairman and CSO |
| Appointee's previous position | Director and CSO |
| Appointee's date of birth | 19 July 1960 |
| Year the appointee joined the Company | 2006 |
| Number of shares held by the appointee | 9,980,000 shares (as of 9 September 2026) |
| Reason for change | To respond to changes in the business environment surrounding the Company, further accelerate efforts to grow existing businesses and create new businesses, strengthen the management structure and speed up decision-making, the Company will transition to a co-representative structure with 2 representative directors and further reinforce its management foundation. Having the founder join the core of management as a representative director will further strengthen the Company's commitment to the research and development of regenerative medicine and accelerate these efforts. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To respond to changes in the business environment, accelerate the growth of existing businesses and the creation of new businesses, strengthen the management structure and speed up decision-making. Founder Tamai Katsuhito (玉井 克人) will join the core of management as a representative director, further strengthening his commitment to the research and development of regenerative medicine.